HCV Symposium

The positive impact of HCV treatment on morbidity and mortality remains underappreciated, as evidenced by the recent proposed report of the USPSTF. This program will emphasize the latest data on improved clinical outcomes and also highlight the latest antiviral therapies that continue to increase the rates of sustained virological response. Combined, this clinical information will provide important motivation for healthcare providers to discuss HCV treatment options with their patients. It will also provide them with the knowledge to select the best individual options from a variety of available treatment options expected to be approved over the next 6-12 months.